Sandoz Group AG / Key word(s): Agreement Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets 18.03.2026 / 08:30 CET/CEST MEDIA RELEASE   Agreement for up to five biosimilar assets, with potential for further collaboration; first asset  [ … ]

Sandoz Group AG / Key word(s): Bond Sandoz issues CHF 550 million in bonds and extends its USD  2 billion revolving credit facility by one year 11.03.2026 / 07:00 CET/CEST MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Dual-tranche CHF bond issuance with total principal amount of CHF [ … ]

Sandoz Group AG / Key word(s): Regulatory Approval Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications 18.02.2026 / 07:00 CET/CEST MEDIA RELEASE Approved indications now include all retinal indications, in addition to previously-approved indication of nAMD More than 30 [ … ]

Sandoz Group AG / Key word(s): Regulatory Approval Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes 14.01.2026 / 12:00 CET/CEST Biosimilar Ondibta® (insulin glargine) approved for treatment of diabetes mellitus across all indicati [ … ]

Sandoz Group AG / Key word(s): Conference Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity 12.01.2026 / 15:00 CET/CEST After consistently delivering on commitments in first two years as standalone compan [ … ]